Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06542614 |
| Consolidated Lead Sponsor | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 209 participants (ACTUAL) |
| Registered Start Date | 2024-08-27 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Beijing Tongren Hospital, Capital Medical University | Beijing, China | Open Hospital Dossier -> |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, China | Open Hospital Dossier -> |
| Liuzhou People's Hospital | Liuzhou, China | Open Hospital Dossier -> |
| The Second Hospital of Hebei Medical University | Shijiazhuang, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.